Page last updated: 2024-11-07

desmethylcarvedilol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desmethylcarvedilol: metabolite of carvedilol; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155763
CHEMBL ID2440861
CHEBI ID175128
SCHEMBL ID8291496
MeSH IDM0148039

Synonyms (28)

Synonym
CHEBI:175128
o-desmethylcarvedilol
72956-44-6
2-[2-[[3-(9h-carbazol-4-yloxy)-2-hydroxypropyl]amino]ethoxy]phenol
demethylcarvedilol
FT-0666097
FT-0666096
FT-0666095
desmethylcarvedilol
phenol, 2-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)ethoxy)-
unii-w0hiu4li95
w0hiu4li95 ,
o-desmethyl carvedilol
CHEMBL2440861
SCHEMBL8291496
bm-14242
desmethylcarvedilol, (+/-)-
2-(2-{[3-(9h-carbazol-4-yloxy)-2-hydroxypropyl]amino}ethoxy)phenol
desmethyl carvedilol
AKOS030255788
2-(2-(3-(9h-carbazol-4-yloxy)-2-hydroxypropylamino)ethoxy)phenol
(s)-(-)-o-desmethylcarvedilo
BCP16902
o-desmethyl carvedilol
2-[2-({3-[(9h-carbazol-4-yl)oxy]-2-hydroxypropyl}amino)ethoxy]phenol
DTXSID60993727
Q27292144
o-desmethylcarvedilol-d5

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This study aims to investigate the implications of type 2 diabetes (T2DM) on the pharmacokinetics of carvedilol enantiomers using an integrated population pharmacokinetic modelling approach."( Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Coelho, EB; Della Pasqua, O; Lanchote, VL; Nardotto, GHB, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Carvedilol Pathway, Pharmacokinetics114

Bioassays (1)

Assay IDTitleYearJournalArticle
AID777140Inhibition of RyR2 R4496C mutant (unknown origin)-mediated store-overload induced calcium release expressed in HEK293 cells after 8 to 10 mins by fura-2/AM dye-based fluorescence assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.42 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]